Positive Results In A Difficult-To-Treat Indication
While the results are early, only being studied in mouse and rat models to date, the data is promising. The truth of the matter is that there is a significant need for new therapeutic options in liver disease.
Although this condition is a highly prevalent one, there are absolutely no FDA approved therapies for treatment. Instead, doctors largely recommend diet and activity, leading to weight loss. After all, weight loss will lead to less fat in the liver.
Considering that there are no FDA approved treatment options for patients, it’s easy to see that NASH is a difficult-to-treat indication. Given these early results, it seems as though HEPA may be onto something meaningful here.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Click Below To Continue Reading.